Back to search results

Digital Detection of Dementia (D Cubed) Studies: D3

This study, called D3, is looking for better ways to find Alzheimer's disease and related dementias (ADRD) earlier. It's testing a "Passive Digital Marker" (PDM), which is a computer program that uses information from your electronic health records to predict if someone might develop ADRD. The goal is to see if using the PDM can help doctors diagnose ADRD sooner in primary care clinics. You might be able to join if you are 65 or older, have visited your primary care doctor in the last year, can give informed consent, speak English or Spanish, and have at least three years of electronic health record data. The study aims to measure how many new ADRD diagnoses are made over 12 months.

Study design
This interventional study plans to include 3150 participants. It will involve primary care clinics where patients' electronic health record data will be analyzed by the PDM.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, incidence of ADRD, is measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06224205

Digital Detection of Dementia (D Cubed) Studies: D3

Completed
NAAges 65+InterventionalScreening
Indiana University
~1,281 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:Passive Digital Marker for screening for ADRD

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of ADRD
Measured over 12 months

Conditions

Alzheimer Disease and Related Dementias (ADRD)

Explore related trials

Alzheimer Disease and Related Dementias

NCT06224205

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Miami School of Medicine

    Boca Raton, Floridano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Malaz Boustani, MD, MPH · PRINCIPAL_INVESTIGATOR · Indiana University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

65 years or older
At least one visit to primary care practice within the past year
Ability to provide informed consent
Ability to communicate in English or Spanish
Available EHR data from at least the past three years

Exclusion

Prior ADRD or mild cognitive impairment diagnosis as determined by ICD-10 code
Evidence of any history of prescription for a cholinesterase inhibitors or memantine.
Has serious mental illness such as bipolar or schizophrenia as determined by ICD-10 code
Permanent resident of a nursing facility

What this trial measures

  • Incidence of ADRD12 months

    The primary outcome measure will be any new ADRD case identified (documented in the EHR) within 12 months of the Annual Wellness Visit (index visit).